国际医药卫生导报2024，Vol.30Issue(7)：1190-1194,5.DOI:10.3760/cma.j.issn.1007-1245.2024.07.027
贝伐珠单抗联合TC方案治疗晚期复发性卵巢癌患者的效果
Bevacizumab combined with TC regimen in treatment of patients with advanced recurrent ovarian cancer
摘要
Abstract
Objective To explore the effect of bevacizumab combined with the TC(paclitaxel/carboplatin)regimen in the treatment of patients with advanced recurrent ovarian cancer.Methods Ninety-two patients with recurrent advanced ovarian cancer treated at Hanzhong Central Hospital from November 2017 to November 2022 were selected for the randomized controlled trial,and were divided into a control group and an observation group by the random number table method,with 46 cases in each group.The control group were(52.34±8.45)years old;there were 24 cases of stage Ⅲ and 22 cases of stage Ⅳ of International Federation of Gynecology and Obstetrics(IFGO).The observation group were(53.21±9.67)years old;there were 23 cases of stage Ⅲ and 23 cases of stage Ⅳ of FIGO.The control group were treated by the TC regimen;in addition,the observation group took bevacizumab.The clinical efficacies,serum levels of tumor markers[carbohydrate antigen 125(CA125),human epididymis protein 4(HE4),carbohydrate antigen 199(CA199),and vascular endothelial growth factor(VEGF)],one-year survival rates,and quality of life[evaluated by Karnofsky Performance Status(KPS)]after the treatment,and adverse reactions were compared between the two groups.t and x2 tests were applied.Results After six cycles of treatment,the disease remission rate in the observation group was higher than that in the control group[78.26％(36/46)vs.54.35％(25/46);x2=7.771,P=0.005];the levels of CA125,HE4,CA199,and VEGF in the observation group were lower than those in the control group(all P＜0.05).The one-year survival rate after the treatment in the observation group was higher than that in the control group[73.91％(34/46)vs.46.65％(21/46);x2=7.640,P=0.006].The score of KPS in the observation group was higher than that in the control group[(72.52±8.13)vs.(64.60±7.58);t=4.832,P＜0.001].The main adverse reactions in both groups were bone marrow suppression,gastrointestinal reactions,and hepatic and renal damage;there were no statistical differences in the incidences of these reactions between the two groups(all P＞0.05).Conclusion Bevacizumab combined with the TC regimen in the treatment of patients with recurrent advanced ovarian cancer has good clinical efficacy,can improve their one-year survival rate and quality of life and reduce the serum levels of tumor markers,and has controllable adverse reactions.关键词
贝伐珠单抗/晚期复发性卵巢癌/疗效/肿瘤标志物/不良反应Key words
Bevacizumab/Advanced recurrent ovarian cancer/Efficacy/Tumor markers/Adverse reactions引用本文复制引用
岳红,陈文华,范志刚,张淑莲,常捷芳..贝伐珠单抗联合TC方案治疗晚期复发性卵巢癌患者的效果[J].国际医药卫生导报,2024,30(7):1190-1194,5.基金项目
陕西省卫生健康委科研基金(2022D068) Scientific Research Foundation of Shaanxi Health Commission(2022D068) （2022D068）
